focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

Share Price Information for Netscientific (NSCI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 69.00
Bid: 68.00
Ask: 70.00
Change: 0.00 (0.00%)
Spread: 2.00 (2.941%)
Open: 69.00
High: 69.00
Low: 69.00
Prev. Close: 69.00
NSCI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Wanda Launches CareLink, New Digital Health App

15 Aug 2018 07:00

RNS Number : 7719X
NetScientific PLC
15 August 2018
 

 

 

NetScientific plc

("NetScientific" or the "Group")

 

Wanda launches new digital health app Wanda CareLink™ with enhanced real-time capabilities on iOS and Android devices

 

London, UK - August 15, 2018 - NetScientific plc ("NetScientific", AIM:NSCI), the transatlantic healthcare IP commercialisation Group, announces that portfolio company Wanda, which uses machine learning to help healthcare providers to better manage the risk and care of patients, has launched its new digital health application Wanda CareLink™. This application allows the Wanda Patient Management solution to be used on a wide variety of internet-enabled devices including iOS and Android devices. This enhances the ability for patients and doctors alike to improve clinical and financial outcomes.

 

The application is available on the Apple Store and is to become available on Google Play shortly.

 

Commenting on the news, Francois R. Martelet, NetScientific's Chief Executive Officer and Chairman of Wanda, said: "Wanda continues to improve its capabilities to match the needs of the market and its clients, and we believe that it will result in increased traction as healthcare providers realise the value of remote patient monitoring from both a financial and clinical standpoint. We are pleased to see Wanda's progress in strengthening its core offering and look forward to further progress."

 

NetScientific holds a 62% stake on a fully diluted basis in Wanda. The full announcement is included below.

 

For more information, please contact:

 

  NetScientific

François R. Martelet, M.D., CEO

Ian Postlethwaite, CFO

Tel: +44 (0)20 3514 1800

Wanda, Inc.

Bill Basset, CCO

Tel: +1 (0)206 910 0428

Consilium Strategic Communications

Mary-Jane Elliott / Chris Welsh / Laura Thornton

 

 

Tel: +44 (0)20 3709 5700

netscientific@consilium-comms.com

WHIreland (NOMAD and Broker)

Chris Fielding / Jessica Cave / Chris Viggor

Tel: +44 (0)20 7220 1666

 

 

About NetScientific

 

NetScientific is a transatlantic healthcare technology group with an investment strategy focused on sourcing, funding and commercialising technologies that significantly improve the health and well-being of people with chronic diseases. For more information, please visit the website at www.netscientific.net

 

 

Predictive Patient Management Platform Expands Real-Time Mobile Capabilities

August 15, 2018 (San Francisco, CA) -- Wanda is pleased to announce the release of its new digital health application Wanda CareLink™. The multi-platform application greatly expands the mobility of the Wanda Patient Management solution to be used on virtually any internet-enabled device including iOS and Android smartphones and tablets. The "bring-your-own-device" approach expands the ability for patients, doctors, and clinicians to improve care plan adherence producing better clinical and financial outcomes. 

The Wanda platform empowers doctors and clinicians with the ability to know when patients will have adverse events before they happen, predicting 90% of rehospitalizations and emergency department visits seven days before they occur. The embedded predictive algorithms identify high-risk patients, alerting doctors and clinicians to the root-causes triggering the adverse events. These insights help clinical teams to assess care plans and proactively manage virtual interventions, which improve patient care plan adherence and resolve the adverse event before it happens.

"Wanda is proving to be a great solution for supporting preventative patient engagement with 74% of patients staying adherent to their care plan," stated William Bassett, Chief Commercial Officer at Wanda. "As high-risk patients are identified, Wanda facilitates better decision making, empowering doctors and clinicians with the real-time insight that will keep patients from preventable emergent situations."

The Wanda application was created from twelve years of research at UCLA, in a collaborative research project including the Medical, Nursing and Engineering Schools. After eight clinical trials yielding nine patents, the machine learning clinical algorithms have shown to predict 90% of adverse events, rehospitalizations and ED visits, seven days before the event will occur. Wanda warns of the pending adverse event detailing the risk triggers for each patient prompting the need for intervention and then facilitates clinical case management.

"Providers and payers can more easily identify and eliminate issues that have made population health and risk-based contracting a challenge," said Ahsan Samiee, Chief Technology Officer at Wanda. "The embedded data science in Wanda can now be used across a range of mobile tools to expand the efficiency of real-time patient care."

 

About Wanda, Inc.

Wanda is dedicated to advancing the effectiveness and efficiency of medicine by using machine learning and modern software applications that empower payers and providers to better manage the risk and care of patients dramatically lowering the cost of care and improving outcomes. More information about Wanda can be found at http://www.yourwanda.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCLLFEITFISLIT
Date   Source Headline
1st Oct 20157:00 amRNSHalf Yearly Report
18th Sep 20157:00 amRNSDivestment of Shareholding in Frontier BioSciences
16th Sep 20151:01 pmRNSHolding(s) in Company
15th Sep 20157:00 amRNSVortex BioSciences granted critical patent
9th Sep 20151:00 pmRNSSteve Curd appointed as CEO of Wanda
7th Aug 20157:00 amRNSDivestment of non-core assets to align portfolio
4th Aug 20157:00 amRNSProAxsis launches first-in-class ProteaseTag test
15th Jul 20157:00 amRNSKey patent granted for Glucosense's technology
22nd Jun 20151:19 pmRNSResults of Annual General Meeting
22nd Jun 20157:00 amRNSAGM Statement
5th Jun 20155:46 pmRNSNotification of Major Interest in Shares
5th Jun 20155:42 pmRNSNotification of Major Interest in Shares
5th Jun 20155:38 pmRNSNotification of Major Interest in Shares
5th Jun 20152:00 pmRNSNotification of Major Interest in Shares
5th Jun 20152:00 pmRNSNotification of Major Interest in Shares
28th May 201512:02 pmRNSPDS Biotechnology reports positive Phase I results
18th May 20157:00 amRNSNotice of AGM and Annual Report & Accounts
15th May 20157:00 amRNSCapital Markets Day
11th May 20157:00 amRNSDr. François R. Martelet appointed as CEO
7th May 20157:00 amRNSNetScientific invests in Neumitra
1st May 20157:00 amRNSNetScientific Forms New Digital Health Company
29th Apr 20159:00 amRNSNetScientific Capital Markets Day
1st Apr 20157:00 amRNSChange of Adviser
24th Mar 20157:00 amRNSSignificant Progress in core Portfolio Companies
20th Mar 20152:00 pmRNSNotice of Full Year Results
26th Feb 201510:07 amRNSAppointment of Non-Executive Director
16th Jan 20156:19 pmRNSDirectorate Change
7th Jan 20151:04 pmRNSNetScientific teams up with KU Leuven
7th Jan 20151:04 pmRNSNetScientific invests in DName-iT
15th Dec 20147:00 amRNSNetScientific invests in PDS Biotechnology
11th Dec 20147:00 amRNSNetScientific enters into alliance with Healthbox
8th Dec 20147:00 amRNSNetScientific invests in Breakout Labs' portfolio
17th Nov 20143:36 pmRNSHolding(s) in Company
17th Nov 20141:26 pmRNSHolding(s) in Company
3rd Oct 20147:00 amRNSSubsidiary, Glycotest collaboration with Oncimmune
23rd Sep 20147:00 amRNSHalf Yearly Report
17th Sep 20142:00 pmRNSNotice of Half Yearly Report
29th Jul 20144:23 pmRNSNetScientific announces shareholder name change
23rd Jul 20148:27 amRNSNetScientific Invests in Breakout Labs Companies
21st Jul 201411:43 amRNSTR1 - Notification of Major Interest in Shares
11th Jul 201411:50 amRNSTR1 - Notification of Major Interest in Shares
4th Jul 20142:11 pmRNSNotification of Major Interest In Shares
2nd Jul 20147:00 amRNSResearch Programme in DNA Sequencing
9th Jun 20144:34 pmRNSNetScientific plc
20th May 20145:33 pmRNSResult of AGM
20th May 20147:00 amRNSAGM Statement
19th May 20147:00 amRNSAnnouncement of research agreement with Harvard
8th May 201410:18 amRNSPosting of Annual Report and Notice of AGM
26th Mar 20147:00 amRNSNetScientific Partners with Breakout Labs
19th Mar 20147:00 amRNSPreliminary results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.